Reported 7 months ago
The U.S. Department of Health and Human Services announced funding of up to $500 million for mid-stage trials of COVID-19 vaccines delivered as a nasal spray or pill to provide symptomatic protection. This funding is a part of Project NextGen, a $5 billion initiative led by BARDA to develop new vaccines for broader and more durable protection against COVID-19. Companies like Vaxart, Castlevax, and Cyanvac are receiving grants to develop oral and intranasal vaccine candidates, with trials enrolling 10,000 volunteers to compare efficacy and safety with FDA-licensed vaccines.
Source: YAHOO